KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three EMERGENT trials that led to its FDA approval.CME: Take the CME Post-Test for this Episode (https://www.thecarlatreport.com/blogs/2-the-carlat-psychiatry-podcast/post/4842-cobenfy-a-new-antipsychotic)Published On: 10/07/2024Duration: 12 minutes, 28 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.